New study suggests BPC-157 may support tendon recovery
Researchers report measurable improvements in animal models of tendon healing.
by Editorial team
What the study looked at
Researchers at a European university examined how BPC-157 — a short peptide derived from a protective protein in the human stomach — influenced healing in a controlled animal model of Achilles tendon injury.
Two groups of rats received standardized tendon injuries. One group was given a daily dose of BPC-157 intraperitoneally for 14 days. The control group received saline. Both were assessed using histology, tensile strength testing, and blood markers for inflammation.
Key findings
The BPC-157 group showed roughly 28% greater tensile strength in the repaired tendon by day 14, compared to the control group. Collagen organization under the microscope was also noticeably more aligned — a marker associated with stronger long-term repair.
Inflammation markers (IL-6 and TNF-α) trended lower in the treatment group across the second week, suggesting the peptide may help modulate the early inflammatory response rather than suppress it outright.
What it does not mean
This is an animal study. While the results are encouraging and consistent with earlier BPC-157 work, no human trials have replicated them yet. Dosing, timing, and route of administration in humans remain open questions.
It also does not mean BPC-157 is risk-free. The peptide is not FDA-approved for any human use, and its long-term safety profile in people is not well characterized.
Why it matters
BPC-157 is one of the most-discussed peptides in the recovery and longevity spaces. Most claims online stem from a small number of animal studies. Each new well-designed paper adds important context — and this one strengthens the case for funding a proper human trial.